Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data
Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data
Equillium Inc. (NASDAQ:EQ) announced Tuesday topline data from its Phase 2, single-dose, proof-of-concept (PoC) study of EQ101 in adult patients with alopecia areata.
Equillium公司（NASDAQ：EQ）週二宣佈了其用於治療斑禿患者的EQ101單劑量概念驗證（PoC）II期研究的前期數據。
Alopecia is an autoimmune disease that attacks the body's hair follicles, causing patchy hair loss.
斑禿是一種自身免疫性疾病，會攻擊人體的毛囊，導致局部脫髮。
The primary objectives of the study were to evaluate the safety and tolerability profile of EQ101 and signs of efficacy using Severity of Alopecia Tool (SALT) scores, where a score of 100 represents total scalp hair loss and a score of 0 represents no scalp hair loss.
該研究的主要目標是評估EQ101的安全性和耐受性，以及使用斑禿嚴重度評分（SALT分數）的療效表現。其中100分代表頭皮全部脫髮，0分代表頭皮無脫髮。
Study results demonstrated a favorable safety and tolerability profile. No serious adverse events and improvements in SALT scores were above the published historically low placebo response rates.
研究結果顯示了EQ101具有良好的安全性和耐受性。無嚴重不良事件發生，並且SALT評分的改善超過了歷史上低的安慰劑反應率。
Of all subjects that completed 24 weeks of treatment (baseline SALT of 35 to 100, n=25); 20% achieved a SALT score of less than or equal to 20 by week 24.
所有完成24周治療的受試者（基線SALT爲35至100，n=25）中，有20%在第24周時達到了SALT評分小於或等於20分。
Of those subjects with moderate to severe AA at baseline that completed 24 weeks of treatment (SALT score 35 to < 95, n=17), 29% achieved a SALT score of less than or equal to 20 by week 24, and a mean SALT improvement from baseline of 18%.
在所有基線爲中等至重度斑禿且已完成24周治療的受試者中（SALT評分爲35至
"Placebo rates in this indication across studies have been consistently low — generally less than 10% of patients achieve a SALT score of 20 or less. To have 20% of patients completing the study reach a SALT score of less than or equal to 20 across all subjects, and 29% of moderate and severe patients, is a very encouraging sign of drug activity," said principal investigator Rodney Sinclair.
“在這種情況下，安慰劑的反應率從各項研究數據來看一直都很低，一般不到10%的患者能夠達到SALT評分小於或等於20分。具有20%的受試者在所有受試者中，以及在中等和重度患者中有29%的患者達到SALT評分小於或等於20分，這是一種非常鼓舞人心的藥物活性表現。”首席研究員Rodney Sinclair說。
The company says preliminary data indicate reductions of cell surface CD132 on CD8 and NK cells in peripheral blood consistent with EQ101 target engagement and pharmacodynamic response.
該公司稱初步數據顯示，與EQ101靶向作用和藥效反應一致，外周血中CD8和NK細胞表面CD132的水平降低。
"We look forward to transitioning to a subcutaneous delivery in placebo-controlled, dose and regimen optimization studies where we expect to continue to investigate EQ101 across alopecia areata disease severity subgroups, including the important population of moderate patients with a SALT score between 35 and less than 50," said Maple Fung, chief medical officer at Equillium.
“我們期待通過皮下給藥在安慰劑對照的用藥方案和劑量優化研究中繼續調查所有斑禿嚴重度亞組，包括SALT評分在35至50之間的中等患者這個重要人群。”Equillium醫療總監Maple Fung說。
Price Action: EQ shares are down 21.8% at $1.15 at last check Tuesday. During premarket trading, the shares reached as high as $1.96.
股價動態：週二最後一次檢查時，EQ股票下跌21.8%，報價1.15美元。在盤前交易期間，股價最高達到1.96美元。
Now Read: Roaring Kitty's GameStop Options Could Be Worth $54M, But Cashing Out Might Be Tricky
現在閱讀：Roaring Kitty的GameStop期權可能價值5400萬美元，但兌現可能會很棘手